A medicinal product shall be designated as an orphan medicinal product if its sponsor can establish:
(a) that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10 thousand persons in the Community when the application is made ...
